Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

A. Nagler, M. Ngoya, JE. Galimard, M. Labopin, IW. Blau, N. Kröger, T. Gedde-Dahl, T. Schroeder, D. Burns, U. Salmenniemi, A. Rambaldi, G. Choi, R. Peffault de Latour, J. Vydra, H. Sengeloev, M. Eder, S. Mielke, E. Forcade, A. Kulagin, F. Ciceri, M. Mohty

. 2024 ; 99 (9) : 1732-1745. [pub] 20240610

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, srovnávací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24019154

We compared relapse incidence (RI) post-unrelated transplantation with post-transplant cyclophosphamide (PTCy) versus no PTCy graft-versus-host disease (GVHD) prophylaxis, in 7049 acute myeloid leukemia (AML) patients in remission, 707 with PTCy, and 6342 without (No PTCy). The patients in the PTCy group were younger, 52.7 versus 56.6 years (p < .001). There were more 9/10 donors in the PTCy group, 33.8% versus 16.4% (p < .001), and more received myeloablative conditioning, 61.7% versus 50.2% (p < .001). In the No PTCy group, 87.7% of patients received in vivo T-cell depletion. Neutrophil and platelet engraftment were lower in the PTCy versus No PTCy group, 93.8% and 80.9% versus 97.6% and 92.6% (p < .001). RI was not significantly different in the PTCy versus the No PTCy group, hazard ratio (HR) of 1.11 (95% confidence interval [CI] 0.9-1.37) (p = .31). Acute GVHD grades II-IV and III-IV, were significantly lower in the PTCy versus the No PTCy group, HR of 0.74 (95% CI 0.59-0.92, p = .007) and HR = 0.56 (95% CI 0.38-0.83, p = .004), as were total and extensive chronic GVHD, HRs of 0.5 (95% CI 0.41-0.62, p < .001) and HR = 0.31 (95% CI 0.22-0.42, p < .001). Non-relapse mortality (NRM) was significantly lower with PTCy versus the No PTCy group, HR of 0.67 (95% CI 0.5-0.91, p = .007). GVHD-free, relapse-free survival (GRFS) was higher in the PTCy versus the No PTCy group, HR of 0.69 (95% CI 0.59-0.81, p = .001). Leukemia-free survival (LFS) and overall survival (OS) did not differ between the groups. In summary, we observed comparable RI, OS, and LFS, significantly lower incidences of GVHD and NRM, and significantly higher GRFS in AML patients undergoing unrelated donor-hematopoietic stem cell transplantation with PTCy versus No PTCy GVHD prophylaxis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019154
003      
CZ-PrNML
005      
20241024111728.0
007      
ta
008      
241015s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ajh.27383 $2 doi
035    __
$a (PubMed)38856236
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Nagler, Arnon $u Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel $1 https://orcid.org/0000000207631265
245    10
$a Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation / $c A. Nagler, M. Ngoya, JE. Galimard, M. Labopin, IW. Blau, N. Kröger, T. Gedde-Dahl, T. Schroeder, D. Burns, U. Salmenniemi, A. Rambaldi, G. Choi, R. Peffault de Latour, J. Vydra, H. Sengeloev, M. Eder, S. Mielke, E. Forcade, A. Kulagin, F. Ciceri, M. Mohty
520    9_
$a We compared relapse incidence (RI) post-unrelated transplantation with post-transplant cyclophosphamide (PTCy) versus no PTCy graft-versus-host disease (GVHD) prophylaxis, in 7049 acute myeloid leukemia (AML) patients in remission, 707 with PTCy, and 6342 without (No PTCy). The patients in the PTCy group were younger, 52.7 versus 56.6 years (p < .001). There were more 9/10 donors in the PTCy group, 33.8% versus 16.4% (p < .001), and more received myeloablative conditioning, 61.7% versus 50.2% (p < .001). In the No PTCy group, 87.7% of patients received in vivo T-cell depletion. Neutrophil and platelet engraftment were lower in the PTCy versus No PTCy group, 93.8% and 80.9% versus 97.6% and 92.6% (p < .001). RI was not significantly different in the PTCy versus the No PTCy group, hazard ratio (HR) of 1.11 (95% confidence interval [CI] 0.9-1.37) (p = .31). Acute GVHD grades II-IV and III-IV, were significantly lower in the PTCy versus the No PTCy group, HR of 0.74 (95% CI 0.59-0.92, p = .007) and HR = 0.56 (95% CI 0.38-0.83, p = .004), as were total and extensive chronic GVHD, HRs of 0.5 (95% CI 0.41-0.62, p < .001) and HR = 0.31 (95% CI 0.22-0.42, p < .001). Non-relapse mortality (NRM) was significantly lower with PTCy versus the No PTCy group, HR of 0.67 (95% CI 0.5-0.91, p = .007). GVHD-free, relapse-free survival (GRFS) was higher in the PTCy versus the No PTCy group, HR of 0.69 (95% CI 0.59-0.81, p = .001). Leukemia-free survival (LFS) and overall survival (OS) did not differ between the groups. In summary, we observed comparable RI, OS, and LFS, significantly lower incidences of GVHD and NRM, and significantly higher GRFS in AML patients undergoing unrelated donor-hematopoietic stem cell transplantation with PTCy versus No PTCy GVHD prophylaxis.
650    _2
$a lidé $7 D006801
650    12
$a nemoc štěpu proti hostiteli $x prevence a kontrola $x etiologie $x epidemiologie $7 D006086
650    _2
$a lidé středního věku $7 D008875
650    12
$a cyklofosfamid $x terapeutické užití $x aplikace a dávkování $7 D003520
650    12
$a akutní myeloidní leukemie $x terapie $x mortalita $7 D015470
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a dospělí $7 D000328
650    _2
$a incidence $7 D015994
650    12
$a transplantace hematopoetických kmenových buněk $x metody $x škodlivé účinky $7 D018380
650    _2
$a senioři $7 D000368
650    _2
$a mladiství $7 D000293
650    _2
$a recidiva $7 D012008
650    _2
$a mladý dospělý $7 D055815
650    _2
$a příprava pacienta k transplantaci $x metody $7 D019172
650    _2
$a homologní transplantace $7 D014184
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a imunosupresiva $x terapeutické užití $7 D007166
655    _2
$a časopisecké články $7 D016428
655    _2
$a srovnávací studie $7 D003160
700    1_
$a Ngoya, Maud $u EBMT Paris Study Office, Department of Haematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France $u Department of Haematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France
700    1_
$a Galimard, Jacques-Emmanuel $u EBMT Statistical Unit, Paris, France
700    1_
$a Labopin, Myriam $u EBMT Paris Study Office, Department of Haematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France $u Department of Haematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France
700    1_
$a Blau, Igor Wolfgang $u Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany
700    1_
$a Kröger, Nicolaus $u University Hospital Eppendorf, Hamburg, Germany
700    1_
$a Gedde-Dahl, Tobias $u Oslo University Hospital, Rikshospitalet, Oslo, Norway
700    1_
$a Schroeder, Thomas $u University Hospital | Essen, Essen, Germany $1 https://orcid.org/0000000216537959
700    1_
$a Burns, David $u University Hospital Birmingham NHSTrust, Birmingham, UK
700    1_
$a Salmenniemi, Urpu $u HUCH Comprehensive Cancer Center, Helsinki, Finland
700    1_
$a Rambaldi, Alessandro $u Department of Oncology and Hematology, University of Milan and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII Piazza OMS, Bergamo, Italy
700    1_
$a Choi, Goda $u University Medical Center Groningen (UMCG), Groningen, The Netherlands
700    1_
$a Peffault de Latour, Régis $u Saint-Louis Hospital, BMT Unit, Paris, France $1 https://orcid.org/0000000162224753
700    1_
$a Vydra, Jan $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Sengeloev, Henrik $u Rigshospitalet, Herlev, Denmark $1 https://orcid.org/0000000259912958
700    1_
$a Eder, Matthias $u Hannover Medical School, Hannover, Germany
700    1_
$a Mielke, Stephan $u Karolinska University Hospital, Stockholm, Sweden
700    1_
$a Forcade, Edouard $u CHU Bordeaux, Hopital Haut-Leveque, Pessac, France
700    1_
$a Kulagin, Alexander $u RM Gorbacheva Research Institute, Pavlov University, Petersburg, Russia $1 https://orcid.org/0000000295894136
700    1_
$a Ciceri, Fabio $u IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy
700    1_
$a Mohty, Mohamad $u EBMT Paris Study Office, Department of Haematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France $u Department of Haematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France
773    0_
$w MED00000251 $t American journal of hematology $x 1096-8652 $g Roč. 99, č. 9 (2024), s. 1732-1745
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38856236 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111721 $b ABA008
999    __
$a ok $b bmc $g 2201780 $s 1231127
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 99 $c 9 $d 1732-1745 $e 20240610 $i 1096-8652 $m American journal of hematology $n Am J Hematol $x MED00000251
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace